3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer
Cur rently, the search for additional organ-sparing methods of intravesical therapy for non-muscular-invasive bladder cancer (NMIBC) is actively continuing, which could become an effective alternative to standard treatment using the Bacillus Calmette-Guérin (BCG) vaccine. The aim of this work was...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dnipro State Medical University
2023-06-01
|
| Series: | Medičnì Perspektivi |
| Subjects: | |
| Online Access: | https://journals.uran.ua/index.php/2307-0404/article/view/283254 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841563828830076928 |
|---|---|
| author | R.S. Chystiakov F.I. Kostyev O.V. Bondar V.V. Lysenko V.O. Varbanets |
| author_facet | R.S. Chystiakov F.I. Kostyev O.V. Bondar V.V. Lysenko V.O. Varbanets |
| author_sort | R.S. Chystiakov |
| collection | DOAJ |
| description | Cur rently, the search for additional organ-sparing methods of intravesical therapy for non-muscular-invasive bladder cancer (NMIBC) is actively continuing, which could become an effective alternative to standard treatment using the Bacillus Calmette-Guérin (BCG) vaccine. The aim of this work was to analyze the safety profile and long-term results of treatment of patients with the high-risk non-muscular-invasive bladder cancer who received adjuvant intravesical chemotherapy using the Combat BRS HIVEC® device for local hyperthermia (HIVEC® therapy group; n=53) in comparison with patients who received adjuvant therapy after transurethral resection of bladder performed with the Bacillus Calmette-Guérin vaccine (BCG therapy group; n=54). As a result, the median follow-up was 30 months (range 7-36). According to Common Terminology Criteria for Adverse Events (CTCAE) v 5.0, the most relevant side effects in HIVEC®/BCG therapy groups were adverse events grade 1-2: fever – 1%/8%; dysuria – 9%/13%; bladder spasms – 7%/12%; hematuria – 3%/4% and urinary tract infection – 3%/10%. Tumor recurrence was reported in 23 patients receiving intravesical BCG therapy and in 10 patients receiving intravesical hyperthermic chemotherapy (42.6% versus 18.9%, p=0.008). Tumor progression was recorded in 11 patients receiving intravesical BCG therapy and in 4 patients receiving intravesical hyperthermic chemotherapy (20.4% versus 7.5%, p=0.046). The study allows us to conclude that the method of hyperthermic intravesical chemotherapy has a better safety profile compared to intravesical Bacillus Calmette–Guérin vaccine therapy, while such indicators of oncological efficacy as 3-year recurrence-free survival and the incidence of progression were better in the HIVEC® therapy group. |
| format | Article |
| id | doaj-art-375bf20f5e814eb8bb0d5bfc3f177e74 |
| institution | Kabale University |
| issn | 2307-0404 |
| language | English |
| publishDate | 2023-06-01 |
| publisher | Dnipro State Medical University |
| record_format | Article |
| series | Medičnì Perspektivi |
| spelling | doaj-art-375bf20f5e814eb8bb0d5bfc3f177e742025-01-02T23:28:09ZengDnipro State Medical UniversityMedičnì Perspektivi2307-04042023-06-01282647010.26641/2307-0404.2023.2.2832543214753-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancerR.S. Chystiakov0https://orcid.org/0000-0002-7049-7628F.I. Kostyev1https://orcid.org/0000-0001-6480-564XO.V. Bondar2https://orcid.org/0000-0001-8746-1878V.V. Lysenko3https://orcid.org/0000-0002-7200-4954V.O. Varbanets4https://orcid.org/0000-0001-7216-7203Odessa National Medical University, Valikhovskiy lane, 2, Odessa, 65026Odessa National Medical University, Valikhovskiy lane, 2, Odessa, 65026Odessa National Medical University, Valikhovskiy lane, 2, Odessa, 65026Odessa National Medical UniversityOdessa National Medical University, Valikhovskiy lane, 2, Odessa, 65026Cur rently, the search for additional organ-sparing methods of intravesical therapy for non-muscular-invasive bladder cancer (NMIBC) is actively continuing, which could become an effective alternative to standard treatment using the Bacillus Calmette-Guérin (BCG) vaccine. The aim of this work was to analyze the safety profile and long-term results of treatment of patients with the high-risk non-muscular-invasive bladder cancer who received adjuvant intravesical chemotherapy using the Combat BRS HIVEC® device for local hyperthermia (HIVEC® therapy group; n=53) in comparison with patients who received adjuvant therapy after transurethral resection of bladder performed with the Bacillus Calmette-Guérin vaccine (BCG therapy group; n=54). As a result, the median follow-up was 30 months (range 7-36). According to Common Terminology Criteria for Adverse Events (CTCAE) v 5.0, the most relevant side effects in HIVEC®/BCG therapy groups were adverse events grade 1-2: fever – 1%/8%; dysuria – 9%/13%; bladder spasms – 7%/12%; hematuria – 3%/4% and urinary tract infection – 3%/10%. Tumor recurrence was reported in 23 patients receiving intravesical BCG therapy and in 10 patients receiving intravesical hyperthermic chemotherapy (42.6% versus 18.9%, p=0.008). Tumor progression was recorded in 11 patients receiving intravesical BCG therapy and in 4 patients receiving intravesical hyperthermic chemotherapy (20.4% versus 7.5%, p=0.046). The study allows us to conclude that the method of hyperthermic intravesical chemotherapy has a better safety profile compared to intravesical Bacillus Calmette–Guérin vaccine therapy, while such indicators of oncological efficacy as 3-year recurrence-free survival and the incidence of progression were better in the HIVEC® therapy group.https://journals.uran.ua/index.php/2307-0404/article/view/283254non-muscle invasive bladder cancerhyperthermic intravesical chemotherapy |
| spellingShingle | R.S. Chystiakov F.I. Kostyev O.V. Bondar V.V. Lysenko V.O. Varbanets 3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer Medičnì Perspektivi non-muscle invasive bladder cancer hyperthermic intravesical chemotherapy |
| title | 3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer |
| title_full | 3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer |
| title_fullStr | 3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer |
| title_full_unstemmed | 3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer |
| title_short | 3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer |
| title_sort | 3 year experience of hyperthermic intravesical chemotherapy use in patients with high risk non muscular invasive bladder cancer |
| topic | non-muscle invasive bladder cancer hyperthermic intravesical chemotherapy |
| url | https://journals.uran.ua/index.php/2307-0404/article/view/283254 |
| work_keys_str_mv | AT rschystiakov 3yearexperienceofhyperthermicintravesicalchemotherapyuseinpatientswithhighrisknonmuscularinvasivebladdercancer AT fikostyev 3yearexperienceofhyperthermicintravesicalchemotherapyuseinpatientswithhighrisknonmuscularinvasivebladdercancer AT ovbondar 3yearexperienceofhyperthermicintravesicalchemotherapyuseinpatientswithhighrisknonmuscularinvasivebladdercancer AT vvlysenko 3yearexperienceofhyperthermicintravesicalchemotherapyuseinpatientswithhighrisknonmuscularinvasivebladdercancer AT vovarbanets 3yearexperienceofhyperthermicintravesicalchemotherapyuseinpatientswithhighrisknonmuscularinvasivebladdercancer |